MOMENTUM 3 Trial Key Takeaways
Featuring the HeartMate 3™ Left Ventricular Assist Device (LVAD)

MOMENTUM 3 Trial Design
A randomized controlled study

1,028 PATIENTS
69 US CENTERS
6 MONTH RESULTS 294 PATIENTS

MOMENTUM 3 Study Outcomes

TRIAL SUCCESS

86%* of 152 HeartMate 3™ LVAD PATIENTS in the first cohort

ACHIEVED

THE PRIMARY ENDPOINT**

0 INCIDENTS OF SUSPECTED OR CONFIRMED DEVICE THROMBOSIS

*In comparison to 77% of the HeartMate II™ LVAD patients
**Primary endpoint: survival to transplant, recovery or LVAD support free of debilitating stroke (modified Rankin score >3), or re-operation to replace the pump.

HeartMate 3™ LVAD Patient Outcomes

HIGH SURVIVAL RATE

PATIENTS AT 30 DAYS 97%
PATIENTS AT 6 MONTHS 89%

LOW STROKE RATE

7.9% AT 6 MONTHS
2.6% of these were hemorrhagic and 5.3% were ischemic.

SIGNIFICANT IMPROVEMENT IN FUNCTIONAL CAPACITY AND IN QUALITY OF LIFE MEASURES

77% IMPROVED TO CLASS I or II

6-MINUTE WALK DISTANCE

&

from NYHA class IIIB or IV at 6 MONTHS


Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. © 2016 St. Jude Medical, Inc. All Rights Reserved. EM-HM3-1116-0020 | Item approved for international use only.